Furthermore, in vivo delivery of αHer‐CrNC in a HER2‐positive ovarian cancer model could substantially suppress tumor growth, mediated by disruption of the plk1 gene and cellular apoptosis in the tumors. This evidence concerns the gene ERBB2 and ovarian cancer.